combination therapy with glp-1 receptor agonist and sglt2 inhibitor Agonists Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined | Drugs Quadruple therapy (SGLT2i + GLP-1RA
Description
For all pair wise comparisons, Risk ratios (RRs) and 95% Confidence Interval (CI) were used as the meta-analytic measure of association between treatment and the incidence of events
J Biol Chem 289: 2723527245, 2014
In a Phase III trial targeting people with obesity but not diabetes, Novo aimed for 25% weight loss a goal it missed in December
Lucie West in Port St
Daily Support for Metabolic Wellness*
In 2004, for the first time in human study, Nikolaidis L.A, et al
